The MAP Kinase Interacting Serine/Threonine Protein Kinase 2 pipeline drugs market research report outlays comprehensive information on the MAP Kinase Interacting Serine/Threonine Protein Kinase 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the MAP Kinase Interacting Serine/Threonine Protein Kinase 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Central Nervous System, and Dermatology which include the indications Triple-Negative Breast Cancer (TNBC), Non-Small Cell Lung Cancer, Migraine, Neuropathic Pain (Neuralgia), and Dermatology. It also reviews key players involved in MAP Kinase Interacting Serine/Threonine Protein Kinase 2 targeted therapeutics development with respective active and dormant or discontinued products.
The MAP Kinase Interacting Serine/Threonine Protein Kinase 2 pipeline targets constitutes close to 15 molecules. Out of which, approximately 12 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical, and Discovery stages are 3, 5, and 4 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 1, and 1 molecule.
MAP Kinase Interacting Serine/Threonine Protein Kinase 2 overview
MAP kinase-interacting serine/threonine-protein kinase 2 is an enzyme encoded by the MKNK2 gene. It phosphorylates SFPQ/PSF, HNRNPA1 and EIF4E. It plays a role in the response to environmental stress and cytokines. It appears to regulate translation by phosphorylating EIF4E thus increasing the affinity of this protein for the 7-methylguanosine-containing mRNA cap. It triggers EIF4E shuttling from cytoplasm to nucleus. It acts as a mediator of the suppressive effects of IFNgamma on hematopoiesis.
For a complete picture of MAP Kinase Interacting Serine/Threonine Protein Kinase 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
